National Pi Day: 3.14 things to know about pi this year

In the spirit of the holiday, here are 3.14 things you may not know about pi: 1. No one is certain who discovered pi as we ...

Barack & Michelle Obama’s Higher Ground Signs On As Co-Producer Of Broadway’s Upcoming ‘Proof’ Revival Starring Ayo Edebiri And Don Cheadle

Higher Ground, the media company founded by President Barack Obama and Michelle Obama, will co-produce of the upcoming ...

Barack and Michelle Obama’s Higher Ground Making Broadway Producing Debut With ‘Proof’ (EXCLUSIVE)

Barack and Michelle Obama are making their Broadway producing debut with ‘Proof’ through their Higher Ground production ...
The Guardian

Forget Jim Ratcliffe’s half-apology: to speak of immigrants ‘colonising’ Britain crosses a line and he must fix that

He fused an echo of Enoch Powell with the spirit of the far right’s great replacement theory. This is no way to progress a humane migration debate Has Britain been colonised by immigrants? That is ...
ABC 7 Chicago

House GOP pushes strict proof-of-citizenship requirement for voters ahead of midterm elections

WASHINGTON -- House Republicans rushed to approve legislation on Wednesday that would impose strict new proof-of-citizenship requirements ahead of the midterm elections, a long shot Trump ...
Seeking Alpha

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

- Company to hold conference call and webcast at 8:30 a.m. ET today “These data underscore that impacting pathways beyond only Th2 biology can meaningfully contribute to AD disease activity. EVO301’s ...
Business Wire

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

- Company to hold conference call and webcast at 8:30 a.m. ET today PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage ...
Morningstar

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

- Company to hold conference call and webcast at 8:30 a.m. ET today Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies ...